查看购物车
  • Traditional Chinese
  • English
  • Japanese
美国前列腺癌检测市场：国家分析：按生物标记类型、按癌症类型、按应用、按最终用户、按地区 - 分析和预测（2025-2035 年）
市场调查报告书
商品编码
1711584

美国前列腺癌检测市场：国家分析：按生物标记类型、按癌症类型、按应用、按最终用户、按地区 - 分析和预测（2025-2035 年）

U.S. Prostate Cancer Testing Market - A Country Analysis: Focus on Type of Biomarker, Cancer Type, Application, End User, and Region - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 120 Pages | 商品交期: 1-5个工作天内

价格

预计美国前列腺癌检测市场的成长将受到癌症研究领域的大量投资和美国前列腺癌盛行率上升的推动。

此外，企业领导者的重点是透过深入了解美国前列腺癌检测市场来满足临床研究中未满足的需求。

美国前列腺癌检测市场正处于发展阶段。近几十年来，对一般人群进行 PSA筛检或检测增加了前列腺癌的发生率。前列腺癌检测对于精准医疗也至关重要，以确保安全和成功的个人化治疗。美国前列腺癌检测市场的大多数公司提供基于尿液、血液或组织的生物标记检测或检测服务。此外，前列腺癌检测的应用主要在临床和研究方面。

未来几年美国前列腺癌检测市场将扩大的主要原因之一是前列腺癌患者数量的增加。前列腺癌是男性第二大常见疾病，其发生率在全球范围内呈上升趋势。据估计，全球每年新增前列腺癌病例一百万例。由于人口老化、都市化加快以及相关的生活方式改变，过去几十年来前列腺癌的总体发病率有所增加。

根据生物标记类型，美国前列腺癌检测市场的切片检查前测试预计将由生物标记类型部分主导。这是由于前列腺癌检测日益普及以及人们对前列腺癌检测相关知识的认识不断提高。

根据癌症类型，前列腺腺癌占美国前列腺癌检测市场的最大份额。这是由于前列腺癌发生率不断上升以及前列腺癌检测日益普及。

从应用角度来看，美国前列腺癌检测市场以诊断生物标记领域为主，这得益于专注于前列腺癌检测开发的研究和开发活动不断增加。正在开发新的基于分子的诊断技术来诊断前列腺癌。在诊断时检测临床相关的癌症需要多种工具和治疗方案来改善患者的生活品质。

从最终用户来看，美国前列腺癌检测市场以门诊手术中心（ASC）为主，这得益于 ASC 数量的不断增长。 ASC 致力于提供当日手术护理，包括测试和保护程序。 ASC 在提供高品质护理和成功的患者治疗结果方面有着良好的记录，并透过为患者提供医院门诊手术的便利选择，改变了数百万美国人的门诊体验。

美国前列腺癌筛检市场的最新趋势

  • 2022 年 9 月，Veracyte 公司在《美国国家癌症研究所杂誌》上发表的数据显示，该公司的解密前列腺基因资料可能有助于识别患有早期局限性前列腺癌且更有可能持有更具侵袭性的疾病的非裔美国男性。
  • 2019 年 8 月，BioReference Laboratories, Inc. 宣布已被美国 IPA 协会 (TIPAAA) 选为实验室服务提供者，协助分析会员的病患资料。该协议旨在加强患者照护并为代表 39 个州的 667 多个医疗保健组织的 TIPAAA 成员提供协作健康管理工具。 TIPAAA 会员可以轻鬆存取 BioReference 的综合测试菜单，包括常规和专科测试以及用于检测进行性前列腺癌的 4Kscore。
  • 2021 年 6 月，赛默飞世尔科技宣布现正接受 Oncomine 临床研究津贴计画的申请，该计画旨在支持肿瘤学临床研究计划。这项津贴旨在资助高品质的分子分析研究，并着重于免疫疗法对癌症患者的影响。

工作流程/创新策略：工作流程部分帮助读者了解两种前列腺癌测试，即初步评估：前列腺特异性抗原（总 PSA、游离 PSA）、切片检查前/切片检查后阴性测试和切片检查后组织测试，进一步帮助诊断。此外，本研究也让读者详细了解前列腺癌检测在临床和研究应用上的各种应用。

成长/行销策略：前列腺癌检测用于研究和临床应用。各公司提供尿液、血液和组织生物标记来辅助诊断，这也是美国前列腺癌检测市场参与企业在当前美国前列腺癌检测市场中取得优势的关键策略。

竞争策略：该研究分析并概述了美国前列腺癌检测市场的主要企业，包括参与新产品发布、收购、业务扩展和策略联盟的製造商。此外，对美国前列腺癌检测市场新参与企业的详细竞争基准化分析有助于读者了解清晰的市场格局，并了解参与企业之间的竞争情况。此外，合作伙伴关係、协议和合作等全面的竞争策略可帮助读者了解美国前列腺癌市场中尚未开发的收益来源。

主要市场参与企业和竞争对手的摘要

一波新的前列腺癌 (PCa) 生物标记正在出现，其 PCa 特异性高于 PSA 及其异构体，可增强 PCa筛检技术。生物标记是一种分子，它的检测或评估可以揭示超出传统临床特征的疾病细节。生物标记存在于各种地方，包括血液、尿液和组织样本。生物标记可以提供诊断和预后资料，帮助医疗保健专业人员预测疾病，从而为个别治疗选择提供资讯。美国前列腺癌检测市场（按生物标记类型）不包括 PSA 检测，分为切片检查前/切片检查后阴性检测和切片检查后组织检测。

本报告研究了美国前列腺癌检测市场，并概述了市场趋势、生物标记类型、癌症类型、应用、最终用户和地区，以及参与市场的公司概况。

目录

执行摘要

第一章 市场概述

  • 市场足迹和成长潜力
  • 未来的可能性
  • 前列腺癌检测的演变
  • 美国前列腺癌流行病学

第二章产业分析

  • 概述
  • 美国法律要求与框架
  • 专利分析
  • 生物标记在前列腺癌治疗中的作用

第三章 市场动态

  • 概述
    • 影响分析
  • 市场驱动因素
  • 市场限制
  • 市场机会

第四章美国前列腺癌检测市场：竞争格局

  • 概述
  • 企业策略
    • 合併与收购
    • 协同效应活动
    • 业务扩展和资金筹措
  • 商务策略
    • 产品发布和核准
    • 出版品
    • 许可和协议
    • 其他活动
  • 美国报销情况

第五章。美国前列腺癌检测市场（按生物标记类型划分，单位：百万美元），2023 年至 2035 年

  • 概述
  • 初步评估：前列腺特异性抗原（总PSA、游离PSA）
  • 切片检查前/活检后切片检查检测
    • 血液中的生物标记
    • 尿液生物标誌物
    • 影像学诊断
  • 切片检查后的组织检查
  • 切片检查后检查

第六章。美国前列腺癌检测市场（按癌症类型划分，单位：百万美元），2023 年至 2035 年

  • 概述
  • 摄护腺腺癌
  • 小细胞癌
  • 其他的

第七章。美国前列腺癌检测市场，按应用划分，（百万美元），2023-2035

  • 概述
  • 临床诊断生物标记
  • 预后生物标记（Prolaris、OncotypeDx、Decipher 等）

第 8 章。美国前列腺癌检测市场，按最终用户划分，（百万美元），2023 年至 2035 年

  • 概述
  • 癌症研究所
  • 诊断实验室
  • 医院和诊所
  • 门诊手术中心（ASC）
  • 其他的

第九章美国前列腺癌检测市场（按地区划分，单位：百万美元），2023-2035

  • 概述
  • 美国东北部
  • 美国中西部
  • 美国南部
  • 美国西部

第十章 公司简介

  • Abbott
  • Abcam plc.
  • Agilent Technologies, Inc.
  • Bio-Techne.（ExoDx）
  • Cleveland Diagnostics, Inc.
  • Danaher.（Beckman Coulter, Inc.）
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd（FOUNDATION MEDICINE, INC.）
  • HU Group Holdings, Inc.（Fujeribio）
  • Mdxhealth
  • Siemens Healthcare GmbH
  • Myriad Genetics, Inc.
  • NeoGenomics Laboratories
  • OPKO Health, Inc.（GenPath）
  • Veracyte, Inc.
Product Code: BHP1297SB

U.S. Prostate Cancer Testing Market Industry Overview

The growth in the U.S. prostate cancer testing market is expected to be driven by high investments in the field of cancer research and the rising prevalence of prostate cancer in the U.S. In addition, the focus of business leaders is establishing a deep understanding to address the unmet needs in clinical research to understand the U.S. prostate cancer testing market.

Market Lifecycle Stage

The U.S. prostate cancer testing market is in the progressing phase. PSA screening or testing in a general population has increased the incidence of prostate cancer in recent decades. In addition, prostate cancer testing is essential in precision medicine because it assures the safe and successful use of tailored therapies. The majority of the companies in the U.S. prostate cancer testing market provide biomarker tests that are urine, blood, and tissue-based, as well as testing services. Furthermore, applications of prostate cancer testing are primarily clinical and research.

Impact

One of the main reasons for the expansion of the U.S. prostate cancer testing market in the upcoming years is the rise in prostate cancer cases. Prostate cancer is the second most frequent disease diagnosed in men, and its frequency is rising across the globe. Prostate cancer is thought to be diagnosed in one million additional cases worldwide each year. Due to an aging population, growing urbanization, and accompanying lifestyle changes, the overall incidence of prostate cancer has increased over the past few decades.

Market Segmentation:

Segmentation 1: by Biomarker Type

  • Initial Evaluation: Prostate-Specific Antigen (Total PSA, Free PSA)
  • Pre-Biopsy/Post-Negative Biopsy Testing
  • Post-Biopsy Tissue Testing

Based on biomarker type, the pre-biopsy test in the U.S. prostate cancer testing market is expected to be dominated by the biomarker type segment. This is due to the increasing popularity of prostate cancer testing and rising awareness related to prostate cancer testing.

Segmentation 2: by Cancer Type

  • Prostatic Adenocarcinoma
  • Small Cell Carcinoma
  • Other Prostate Cancer Types

Based on Cancer type, prostatic adenocarcinoma accounted for the largest share of the U.S. prostate cancer testing market. This is due to the increasing incidences of prostate cancer and increasing popularity of prostate cancer testing.

Segmentation 3: by Application

  • Diagnostics Biomarkers
  • Prognostics Biomarkers

Based on application, the U.S. prostate cancer testing market is dominated by the diagnostics biomarkers segment owing to the rising R&D activity focused on the development of prostate cancer testing. The diagnosis of prostate cancer has developed a new molecular-based diagnostics technology. To detect clinically relevant cancer upon diagnosis, several tools or therapeutic options are required to improve the patient's quality of life.

Segmentation 4: by End User

  • Cancer Research Institutes
  • Diagnostic Laboratories
  • Hospitals and Clinics
  • Ambulatory Surgical Centers (ASCs)
  • Others

Based on end user, the U.S. prostate cancer testing market is dominated by the ambulatory surgical centers (ASCs) segment owing to their rise in number. They are dedicated to offering same-day surgical care, including testing and protective procedures. ASCs, which have a proven track record of providing high-quality treatment and successful patient outcomes, have altered the outpatient experience for millions of Americans by giving patients a more convenient option for hospital-based outpatient operations.

Segmentation 5: by Region

  • Northeast U.S.
  • Midwest U.S
  • South U.S.
  • West U.S.

Recent Developments in the U.S. Prostate Cancer Testing Market

  • In September 2022, Veracyte, Inc. announced the publishing of data in the Journal of the National Cancer Institute to demonstrate the company's decipher prostate genomic classifier may help identify African American men with early, localized prostate cancer who are most likely to harbor more aggressive disease.
  • In August 2019, BioReference Laboratories, Inc. announced the selection by The IPA Association of America (TIPAAA) as its provider of laboratory services and to assist with data analytics for its members' patients. The agreement is designed to enhance patient care and offers collaborative health management tools to TIPAAA members, which includes more than 667 medical organizations in 39 states. The members can have convenient access to BioReference's comprehensive laboratory testing menu, including routine and specialty tests, as well as the 4Kscore for detecting aggressive prostate cancer.
  • In June 2021, Thermo Fisher Scientific announced submissions open for the Oncomine Clinical Research Grant program to support clinical research projects in oncology. The grant aims to provide funding for high-quality molecular profiling studies focusing on the impact of immune-based treatments for cancer patients.

Demand - Drivers and Limitations

The following are the demand drivers for the U.S. prostate cancer testing market:

  • Rising prevalence of prostate cancer in the U.S.
  • Increasing number of prostate cancer screening and testing
  • Government initiatives related to prostate cancer

The market is expected to face some limitations due to the following challenges:

  • High Probability of false positive results of prostate cancer testing
  • Clinical gaps related to prostate cancer testing

How can this report add value to an organization?

Workflow/Innovation Strategy: The workflow segment helps the reader understand the two prostate cancer testing, i.e., initial evaluation: prostate-specific antigen (total PSA, free PSA), pre-biopsy/post-negative biopsy testing, and post-biopsy tissue testing, which further aid in diagnosis. Moreover, the study provides the reader with a detailed understanding of the different applications of prostate cancer testing in clinical and research applications.

Growth/Marketing Strategy: Prostate cancer testing is being used for both research and clinical application. Various companies are providing urine and blood, and tissue-based biomarkers that aid in the diagnosis, which is also the key strategy for U.S. prostate cancer testing market players to excel in the current U.S. prostate cancer testing market.

Competitive Strategy: Key players in the U.S. prostate cancer testing market are analyzed and profiled in the study, including manufacturers who are involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the U.S. prostate cancer testing market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the U.S. prostate cancer market.

Key Market Players and Competition Synopsis

A new wave of prostate cancer (PCa) biomarkers with greater PCa specificity than PSA and its isoforms have emerged to enhance PCa screening techniques. Biomarkers are molecules that, when detected or assessed, reveal details about a disease that goes beyond conventional clinical characteristics. They can be found in a number of places, including blood, urine, and tissue samples. Both diagnostic and prognostic data can be provided by biomarkers, supporting healthcare professionals in formulating illness projections intended to inform treatment choices on an individual basis. The U.S. prostate cancer testing market (by biomarker type) excluding PSA Tests is segmented into pre-biopsy/post-negative biopsy testing and post-biopsy tissue testing.

Some of the prominent names in the U.S. prostate cancer testing market are:

  • Danaher. (Beckman Coulter, Inc.)
  • Opko Health, Inc. (Genpath, Inc.)
  • Bio-Techne
  • Cleaveland Diagnostics, Inc.
  • mdxhealth
  • Myriad Genetics, Inc.
  • Exact Sciences Corporation
  • Veracyte, Inc.
  • mdxhealth

Companies that are not a part of the aforementioned pool have been well represented across different sections of the report (wherever applicable).

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

Research Methodology

1. Markets Overview

  • 1.1 Market Footprint and Growth Potential
  • 1.2 Future Potential
  • 1.3 Evolution of Prostate Cancer Testing
  • 1.4 Epidemiology of Prostate Cancer in the U.S.
    • 1.4.1 Southern U.S.
    • 1.4.2 Midwest U.S.
    • 1.4.3 Mid-Atlantic U.S.
    • 1.4.4 West U.S.
    • 1.4.5 Southwest U.S.
    • 1.4.6 New England e

2. Industry Analysis

  • 2.1 Overview
  • 2.2 Legal Requirements and Framework in the U.S
    • 2.2.1 National Comprehensive Cancer Network (NCCN) Guidelines
    • 2.2.2 American Urological Association (AUA)
    • 2.2.3 American Cancer Society (ACS)
    • 2.2.4 U.S. Preventive Services Task Force (USPSTF)
  • 2.3 Patent Analysis
    • 2.3.1 Patent Filing Trend
  • 2.4 Role of Biomarkers in Prostate Cancer Management

3. Market Dynamics

  • 3.1 Overview
    • 3.1.1 Impact Analysis
  • 3.2 Market Drivers
  • 3.3 Market Restraints
  • 3.4 Market Opportunities

4. U.S. Prostate Cancer Testing Market: Competitive Landscape

  • 4.1 Overview
  • 4.2 Corporate Strategies
    • 4.2.1 Mergers and Acquisitions
    • 4.2.2 Synergistic Activities
    • 4.2.3 Business Expansions and Funding
  • 4.3 Business Strategies
    • 4.3.1 Product Launches and Approvals
    • 4.3.2 Publications
    • 4.3.3 Licenses and Agreements
    • 4.3.4 Other Activities
  • 4.4 Reimbursement Scenario in the U.S.

5. U.S. Prostate Cancer Testing Market (by Biomarker Type), ($Million), 2023-2035

  • 5.1 Overview
  • 5.2 Initial Evaluation: Prostate-Specific Antigen (Total PSA, Free PSA)
  • 5.3 Pre-Biopsy/Post-Negative Biopsy Testing
    • 5.3.1 Blood-Based Biomarker
    • 5.3.2 Urine-Based Biomarker
    • 5.3.3 Imaging
      • 5.3.3.1 Multiparametric Magnetic Resonance Imaging (mp-MRI)
  • 5.4 Post-Biopsy Tissue Testing
  • 5.5 Post-Biopsy Test

6. U.S. Prostate Cancer Testing Market (by Cancer Type), ($Million), 2023-2035

  • 6.1 Overview
  • 6.2 Prostatic Adenocarcinoma
  • 6.3 Small Cell Carcinoma
  • 6.4 Other Prostate Cancer Type

7. U.S. Prostate Cancer Testing Market (by Application), ($Million), 2023-2035

  • 7.1 Overview
  • 7.2 Clinical Diagnostic Biomarkers
  • 7.3 Prognostic Biomarkers (Prolaris, OncotypeDx, Decipher, etc.)

8. U.S. Prostate Cancer Testing Market (by End User), ($Million), 2023-2035

  • 8.1 Overview
  • 8.2 Cancer Research Institutes
  • 8.3 Diagnostic Laboratories
  • 8.4 Hospitals and Clinics
  • 8.5 Ambulatory Surgical Centers (ASCs)
  • 8.6 Others

9. U.S. Prostate Cancer Testing Market (by Region), ($Million), 2023-2035

  • 9.1 Overview
  • 9.2 Northeast U.S.
    • 9.2.1 Northeast U.S. (Prostate-Specific Antigen (PSA)
    • 9.2.2 Northeast U.S. (Pre-Biopsy/Post-Negative Biopsy Testing)
    • 9.2.3 Northeast U.S. (Post-Biopsy Tissue Testing)
  • 9.3 Midwest U.S.
    • 9.3.1 Midwest U.S. (Prostate-Specific Antigen (PSA)
    • 9.3.2 Midwest U.S. (Pre-Biopsy/Post-Negative Biopsy Testing)
    • 9.3.3 Midwest U.S. (Post-Biopsy Tissue Testing)
  • 9.4 South U.S.
    • 9.4.1 South U.S. (Prostate-Specific Antigen (PSA)
    • 9.4.2 South U.S. (Pre-Biopsy/Post-Negative Biopsy Testing)
    • 9.4.3 South U.S. (Post-Biopsy Tissue Testing)
  • 9.5 West U.S.
    • 9.5.1 West U.S. (Prostate-Specific Antigen (PSA)
    • 9.5.2 West U.S. (Pre-Biopsy/Post-Negative Biopsy Testing)
    • 9.5.3 West U.S. (Post-Biopsy Tissue Testing)

10. Company Profiles

  • 10.1 Abbott
    • 10.1.1 Overview
    • 10.1.2 Top Products / Product Portfolio
    • 10.1.3 Top Competitors
    • 10.1.4 Target Customers/End-Users
    • 10.1.5 Key Personnel
    • 10.1.6 Analyst View
  • 10.2 Abcam plc.
    • 10.2.1 Overview
    • 10.2.2 Top Products / Product Portfolio
    • 10.2.3 Top Competitors
    • 10.2.4 Target Customers/End-Users
    • 10.2.5 Key Personnel
    • 10.2.6 Analyst View
  • 10.3 Agilent Technologies, Inc.
    • 10.3.1 Overview
    • 10.3.2 Top Products / Product Portfolio
    • 10.3.3 Top Competitors
    • 10.3.4 Target Customers/End-Users
    • 10.3.5 Key Personnel
    • 10.3.6 Analyst View
  • 10.4 Bio-Techne. (ExoDx)
    • 10.4.1 Overview
    • 10.4.2 Top Products / Product Portfolio
    • 10.4.3 Top Competitors
    • 10.4.4 Target Customers/End-Users
    • 10.4.5 Key Personnel
    • 10.4.6 Analyst View
  • 10.5 Cleveland Diagnostics, Inc.
    • 10.5.1 Overview
    • 10.5.2 Top Products / Product Portfolio
    • 10.5.3 Top Competitors
    • 10.5.4 Target Customers/End-Users
    • 10.5.5 Key Personnel
    • 10.5.6 Analyst View
  • 10.6 Danaher. (Beckman Coulter, Inc.)
    • 10.6.1 Overview
    • 10.6.2 Top Products / Product Portfolio
    • 10.6.3 Top Competitors
    • 10.6.4 Target Customers/End-Users
    • 10.6.5 Key Personnel
    • 10.6.6 Analyst View
  • 10.7 Exact Sciences Corporation
    • 10.7.1 Overview
    • 10.7.2 Top Products / Product Portfolio
    • 10.7.3 Top Competitors
    • 10.7.4 Target Customers/End-Users
    • 10.7.5 Key Personnel
    • 10.7.6 Analyst View
  • 10.8 F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.)
    • 10.8.1 Overview
    • 10.8.2 Top Products / Product Portfolio
    • 10.8.3 Top Competitors
    • 10.8.4 Target Customers/End-Users
    • 10.8.5 Key Personnel
    • 10.8.6 Analyst View
  • 10.9 H.U. Group Holdings, Inc. (Fujeribio)
    • 10.9.1 Overview
    • 10.9.2 Top Products / Product Portfolio
    • 10.9.3 Top Competitors
    • 10.9.4 Target Customers/End-Users
    • 10.9.5 Key Personnel
    • 10.9.6 Analyst View
  • 10.10 Mdxhealth
    • 10.10.1 Overview
    • 10.10.2 Top Products / Product Portfolio
    • 10.10.3 Top Competitors
    • 10.10.4 Target Customers/End-Users
    • 10.10.5 Key Personnel
    • 10.10.6 Analyst View
  • 10.11 Siemens Healthcare GmbH
    • 10.11.1 Overview
    • 10.11.2 Top Products / Product Portfolio
    • 10.11.3 Top Competitors
    • 10.11.4 Target Customers/End-Users
    • 10.11.5 Key Personnel
    • 10.11.6 Analyst View
  • 10.12 Myriad Genetics, Inc.
    • 10.12.1 Overview
    • 10.12.2 Top Products / Product Portfolio
    • 10.12.3 Top Competitors
    • 10.12.4 Target Customers/End-Users
    • 10.12.5 Key Personnel
    • 10.12.6 Analyst View
  • 10.13 NeoGenomics Laboratories
    • 10.13.1 Overview
    • 10.13.2 Top Products / Product Portfolio
    • 10.13.3 Top Competitors
    • 10.13.4 Target Customers/End-Users
    • 10.13.5 Key Personnel
    • 10.13.6 Analyst View
  • 10.14 OPKO Health, Inc. (GenPath)
    • 10.14.1 Overview
    • 10.14.2 Top Products / Product Portfolio
    • 10.14.3 Top Competitors
    • 10.14.4 Target Customers/End-Users
    • 10.14.5 Key Personnel
    • 10.14.6 Analyst View
  • 10.15 Veracyte, Inc.
    • 10.15.1 Overview
    • 10.15.2 Top Products / Product Portfolio
    • 10.15.3 Top Competitors
    • 10.15.4 Target Customers/End-Users
    • 10.15.5 Key Personnel
    • 10.15.6 Analyst View

List of Figures

  • Figure: U.S. Prostate Cancer Testing Market, Dynamics Impact Analysis
  • Figure: U.S.Prostate Cancer Testing Market Coverage
  • Figure: U.S.Prostate Cancer Testing Market Key Trends, Impact Analysis, 2023-2035
  • Figure: U.S.Prostate Cancer Testing Market, Patent Analysis, January 2022-March 2025

List of Tables

  • Table: U.S. Prostate Cancer Testing Market, Patent Analysis, January 2022-March 2025
  • Table: U.S.Prostate Cancer Testing Market Dynamics, Impact Analysis
  • Table: U.S.Prostate Cancer Testing Market (by Biomarker Type), $Million, 2023-2035
  • Table: U.S.Prostate Cancer Testing Market (by Cancer Type), $Million, 2023-2035
  • Table: U.S.Prostate Cancer Testing Market (by Application), $Million, 2023-2035
  • Table: U.S. Prostate Cancer Testing Market (by End User), $Million, 2023-2035
  • Table: U.S. Prostate Cancer Testing Market (by Region), $Million, 2023-2035